ACER — Acer Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Acer Announces Resubmission Of NDA For Acer-001 For Treatment Of UCDs
Acer up on China patent for genetic disorder treatment
Brief: Acer Therapeutics And Relief Therapeutics Announce That The China National Intellectual Property Administration Issued Utility Model Patent 11,202,767 Covering ACER-001 Dosage Form
Brief: Acer Therapeutics And Relief Therapeutics: China National Intellectual Property Administration (CNIPA) Issued Utility Model Patent
Swiss stocks - Factors to watch on July 8
Acer Therapeutics jumps on starting trial for inherited disorder drug
Brief: Acer Therapeutics Announces Initiation Of Its Pivotal Phase 3 Discover Trial Of Edsivo (Celiprolol) For The Treatment Of Vascular Ehlers-Danlos Syndrome
Acer Therapeutics hits over 2-yr low as FDA declines to approve drug
Brief: Acer Therapeutics Announces Promotion Of Tanya Hayden To Chief Operating Officer
Brief: Acer Therapeutics And Relief Therapeutics Announce Update On U.S. FDA Review Of NDA For Acer-001
U.S. STOCKS ON THE MOVE-Annexon Inc, Mirati Therapeutics, Biodesix Inc
U.S. STOCKS ON THE MOVE-Bluebird bio Inc, JanOne Inc, J.M. Smucker Co
Acer Therapeutics drops as FDA misses action date for genetic disorder drug
Brief: Acer Therapeutics Issues Statement Regarding PDUFA Target Action Date For Acer-001
Brief: Acer Therapeutics Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq
Brief: Acer Therapeutics Filed Supplement Relating To Offer, Sale From Time To Time, With Aggregate Offering Price Of Up To $6.4 Million Shares Of Common Stock
Acer Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Acer Therapeutics Inc expected to post a loss of 41 cents a share - Earnings Preview
Acer Therapeutics rises on agreement with FDA for late-stage trial